COMP <GO>
MCK vs LLY // REVENUE GROWTH (YOY)
McKesson Corporation (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: MCK 6
— LLY 9
▲ REVENUE GROWTH (YOY) LEADER: LLY
LAST: $994.58 (+1.40%) • MKT CAP: $114.36B
revenue-growth
12.40%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
revenue-growth
45.51%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MCK VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MCK | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 3.60% | 83.64% | -80.04 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 38.60% | 32.36% | +6.24 | MCK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.5x | 36.4x | -16.92 | MCK | /valuation <GO> |
| Free Cash Flow Yield | 5.00% | 2.30% | +2.70 | MCK | /fcf-yield <GO> |
| Operating Margin | 1.50% | 40.21% | -38.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 1.20% | 31.90% | -30.70 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 12.40% | 45.51% | -33.11 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.33% | 0.49% | -0.16 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.96 | 9.29 | -2.33 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.77% | -0.07 | MCK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.7 | 77.9 | -17.22 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.51 | +0.44 | MCK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.2x | 26.3x | -6.05 | MCK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $114.36B | $1.33T | -$1.22T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MCK REV | LLY REV | MCK GROSS % | LLY GROSS % | MCK FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $403.43B | $65.18B | 3.6% | 83.0% | $5.72B | $16.81B |
| FY 2024 | $359.05B | $45.04B | 3.7% | 81.3% | $5.55B | $8.82B |
| FY 2023 | $308.95B | $34.12B | 44.0% | 79.3% | -$9.59B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MCK // BETA 0.95
LLY // BETA 0.51